With extensive experience in the life sciences and biotechnology sectors, the fund manager has successfully led over 30 investments across North America and Europe. They emphasize a data-driven approach, targeting early-stage companies that demonstrate innovative potential. Notably, their strategic style has facilitated several high-profile exits, showcasing their ability to identify and nurture disruptive technologies. Their portfolio reflects a commitment to thematic investments that align with emerging trends in the healthcare landscape.